MedTrace Logo

A Study of Laquinimod Eye-drops in Healthy Participants

NCT05187403 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2023-01-31

No results posted yet for this study

Summary

This is a Phase 1 randomized, double-masked, placebo-controlled study performed with healthy participants to assess the safety and tolerability of laquinimod eye-drops.

Conditions

  • Eye Diseases

Interventions

DRUG

Laquinimod

Eye-drops

DRUG

Placebo

Eye-drops

Sponsors & Collaborators

  • Active Biotech AB

    lead INDUSTRY

Principal Investigators

  • Gerhard Garhöfer, MD PhD · Clinical trial center at Medical University Vienna

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-09
Primary Completion
2023-01-19
Completion
2023-01-19

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05187403 on ClinicalTrials.gov